Sign in to view content

Avacincaptad Pegol, A Novel C5 Inhibitor, Reached Statistical Significance in a Pivotal Clinical Trial for Geographic Atrophy Secondary to Dry AMD

Baruch D. Kuppermann, MD, PhD

Video
Published 2020

Related

Episode 199: Nov/Dec 2019 Retinal Physician Preview: New Pathways for Dry AMD
Jayanth Sridhar, MD
Member Podcasts
2019
Clinical and Demographic Factors Associated With Loss to Follow-up in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration
Durga Borkar, MD
Annual Meeting Talks
2021
Evaluation of Baseline Characteristics on Lesion Progression in a Large Phase 2 Clinical Trial for Geographic Atrophy (FILLY Study)
Eleonora Lad, MD, PhD
Annual Meeting Talks
2019

Category: AMD-Neovascular

See more